YOKOGAWA-ELECTRIC
7.4.2020 09:02:09 CEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces the release of artificial intelligence (AI)-enabled versions of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, and GA10 data logging software, which are components of the highly operable and expandable SMARTDAC+TM data acquisition and control system. This new AI functionality includes the future pen, a function developed by Yokogawa that enables the drawing of predicted waveforms. Yokogawa is also releasing a new CPU module for the e-RT3TM Plus edge computing platform that is environmentally robust and PythonTM*1 compatible. The GX/GP and e-RT3 Plus release is set for April 8, and the GA10 software will be released on May 13. The SMARTDAC+ system is a product in the OpreXTM Data Acquisition family, and the e-RT3 Plus is part of the OpreX Control Devices family.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005269/en/
The introduction of AI functions such as the future pen, a first for industrial recorders*2 , will help users identify and correct problems before they have a chance to cause disruptions in production operations.
Background
There is a rising interest in the manufacturing sector in the use of AI to prevent equipment malfunctions and maximize productivity. At the same time, AI technologies have a steep learning curve, and the introduction of existing AI-enabled products and the analysis of their data is typically beyond the expertise of novices to this field.
Recorders are used in manufacturing and R&D to acquire, display, and record data on voltage, current, temperature, flow rate, pressure, and other process variables. Yokogawa is a leading manufacturer of recorders, and also holds a solid track record in the consulting industry with the use of machine learning to predict and analyze both equipment anomalies and product quality for manufacturers. To improve productivity and product quality, Yokogawa is now building user-friendly AI-related functions into its recorders, data logging software, and controllers. For example, these functions now enable GX/GP series recorders to draw waveforms on screen that are predicted based on the real-time analysis of collected data so that users can anticipate and correct problems early on, before they have a chance to escalate. Also, the e-RT3 Plus edge computing platform has been enhanced with the addition of support for Python, a programming language that is widely used in AI R&D.
Enhancements
-
AI future pen function for drawing of predicted waveforms
A future pen function has been added to the GX/GP series recorders to enable the drawing of predicted waveforms based on the use of AI to analyze collected data in real time. By viewing predicted waveforms up to a specified time point, users can identify the likelihood that an alarm will occur and take action in advance. An industry first, this adds an entirely new dimension to the capabilities of recorders, whose collection and recording of data has conventionally been used to visualize the past and present performance of various types of equipment.
-
Detection of anomalies and prediction of potential failures
A machine learning function has been added to the GA10 data logging software that can acquire normal process values from correctly operating devices and use these values to detect an anomaly and predict a potential failure, a capability that up till now has only been possessed by the most expert operators. Data on which device is expected to fail is displayed on screen, highlighted within a yellow frame. Maintenance can thus be performed before the device fails, minimizing the likelihood of any disruptions to production. This function does not necessitate the collection of abnormal process values and thus is easy to implement.
-
Addition of Python support
e-RT3 Plus controllers can be built into various types of devices. For use with these controllers, Yokogawa is releasing a new CPU module that supports Python, a programming language that is widely used in machine learning and other branches of the AI field. The large library of software written in this language includes numerous tools that programmers can use to speed up their development of AI predictive diagnostic functions. This new CPU module also has excellent environmental resistance, and easily accommodates existing input/output (IO) modules. The addition of this new module to the e-RT3 Plus edge computing platform will enable the introduction of AI solutions in a wider range of industries.
For added flexibility, the new e-RT3 Plus controllers run on Linux Ubuntu*3 , a general-purpose operating system.
Major Target Markets
GX series: Production sites in a wide range of industries including iron and steel, electric power, chemicals, pulp and paper, foods, pharmaceuticals, heat treatment equipment, water supply and wastewater treatment, electrical equipment, and electronics
GP series: Companies engaged in R&D of home appliances, automobiles, semiconductors, and new-energy related technologies as well as academic institutions and research institutes
GA10: Both of the above
e-RT3 Plus: Manufacturers of industrial machinery and companies engaged in the assembly of electronic components and devices
Applications
Monitoring and recording of voltage, current, temperature, flow rate, pressure, and other process variables; evaluation of performance in equipment management, production, and product development; safety and reliability evaluation during product quality inspection processes
*1 A versatile programming language that is widely used in AI application development. Designed to be user-friendly with simple code, Python enables users to write various programs in a clear manner with fewer lines of code than other languages. In addition, numerous Python open-source libraries are available for use in machine learning and other AI applications.
*2 Based on a March 2020 Yokogawa survey
*3 A Linux distribution and installation package provided by Canonical Ltd., a UK-based software company
About SMARTDAC+
SMARTDAC+ stands for smart data acquisition and control, and the SMARTDAC+ system includes a variety of IO modules and options. With the product lineup of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, GA10 data logging software, and GM series data acquisition systems, SMARTDAC+ offers extensive support for manufacturing process monitoring and performance evaluation.
For more information
https://www.yokogawa.com/ai-products/
About OpreX
OpreX is the comprehensive brand for Yokogawa's industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa's IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. The SMARTDAC+ data acquisition and control system is part of the OpreX Data Acquisition lineup, which is aligned under the OpreX Measurement category. The OpreX Measurement category includes field equipment and systems for highly precise measurement, data collection, and analysis.
With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.
About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com
.
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005269/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
